Moutaz Sweileh

Dr. Moutaz Sweileh

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2025 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MSMoutaz Sweileh
Moutaz Sweileh
Background: Inherited hematologic disorders such as sickle cell disease (SCD), thalassemia, and hemophilia are rare but devastating conditions with high morbidity and mortality. Advances in gene therapy have opened curative prospects. The objective of the current study was to provide a comprehensive bibliometric and knowledge-mapping analysis of global research on gene therapy targeting SCD, thalassemia, and hemophilia. Methods: A Scopus-based bibliometric search was conducted for the period from 1986 to 2024. The search used title-specific queries for the target diseases and title-abstract queries for gene therapy technologies. Bibliometric indicators and network visualization maps, created by VOSviewer, were presented. Results: A total of 1399 articles were retrieved. Publication growth revealed two phases: a steady, but slow phase (1986–2018), and mature expansion phase (2019–2024), with an average annual growth rate of 28% over the last decade. The articles had a mean of 47.6 citations/article and an H-index of 126. Research was mainly distributed across medicine (39.5%), biochemistry/genetics/molecular biology (30.7%), immunology (8.1%), and pharmacology/toxicology (7.5%), reflecting the multidisciplinary nature of the field. The most prolific journal was Blood (8.6%), followed by Hemophilia , Molecular Therapy , Human Gene Therapy , and Blood Advances . The United Stated dominated the field (n = 863; 61.7%), followed by China and the United Kingdom, with the United States showing strong intra-country collaborations, while European countries demonstrated high international collaborations, often with the United States. Leading institutions included the Children’s Hospital of Philadelphia (7.5%) and University of Pennsylvania (5.9%). Co-authorship analysis revealed robust collaboration networks, with notable clusters around AAV-based hemophilia therapy and CRISPR-mediated gene correction for hemoglobinopathies. Keyword co-occurrence highlighted themes like AAV vectors, genome editing, CRISPR-Case9, and ex vivo hematopoietic stem cell modification. Overlay visualization maps indicated a recent surge in CRISPR and clinical applications research. Conclusions: The bibliometric findings underscore the rapid evolution of gene therapy research for SCD, thalassemia, and hemophilia, moving from experimental approaches to clinical translation. The strong interdisciplinary collaboration, rising clinical trials, and emergence of genome editing tools suggest that the field is entering a transformative era, offering real-world therapeutic solutions for previously incurable inherited blood disorders.

1 May 2025 in Digital Health
Verified
Journal Article
Open access
MSMoutaz Sweileh
Moutaz Sweileh
Objectives: To map global research on AI-driven histopathological image interpretation in oncology (2000–2024). Methodology: Scopus-based bibliometrics using Boolean queries; data exported, cleaned, and analyzed in VOSviewer. Results: The dataset included 1874 publications, surging after 2015. China (n = 561) and the United States (n = 467) led output; leading institutions included Harvard Medical School and the Chinese Academy of Sciences. Top journals were Scientific Reports, Cancers, and IEEE Access; the corpus H-index was 112. Collaboration networks intensified, especially U.S.–Asia. Keyword mapping showed four clusters: (1) deep learning for breast cancer/CNN diagnostics; (2) transfer learning/feature extraction; (3) prognostic modeling/tumor microenvironment; and (4) digital infrastructure/explainable AI. Overlay analyses traced a shift from classical machine learning to transformers and multimodal models integrating molecular and clinical data; emerging themes include semantic segmentation, self-supervised learning, and therapy-response prediction. Applications spanned breast, prostate, colorectal, head–neck, gynecologic, and gastrointestinal/liver cancers. Models primarily used whole-slide images (e.g., TCGA) and multi-omics; algorithms included CNNs, deep learning, classical machine learning, and weakly supervised approaches. Evidence ranged from proof-of-concept to multicenter validation and workflow integration; adoption remains constrained by data standardization, interpretability, and regulation. Clinically, AI improved diagnostic accuracy/efficiency and supported personalization via multi-omics. Bibliographic coupling revealed three clusters: clinical/translational journals; engineering/computational outlets; and interdisciplinary venues linking algorithmic innovation with digital pathology. Conclusions: AI histopathology is advancing toward clinical-grade deployment, propelled by collaboration and methodological innovation, yet limited by data standards, explainability, and regulatory requirements.

3 August 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MSMoutaz Sweileh
Moutaz Sweileh
Background Chimeric Antigen Receptor T cell (CAR-T) therapy is a groundbreaking, personalized immunotherapy that genetically engineers patient or donor-derived T cells to recognize and eliminate cancer cells. The U.S FDA has approved six CAR-T cell products in the past decade. Objective Given their clinical success and scientific novelty, this study aimed to map the research landscape surrounding the FDA-approved CAR-T cell therapies using bibliometric and knowledge mapping analysis. Methods A comprehensive title/abstract search was conducted in Scopus database for documents published between 2015 and 2024. The search terms included generic, trade, and abbreviated names of all FDA-approved CAR-T cell products. Bibliometric indicators including average annual growth rate, citation impact, key contributors, authorship pattern, and international collaboration were assessed. Visualization maps of co-authorship and keyword co-occurrence were generated using VOSviewer. Results A total of 1163 documents were retrieved, with an average annual growth rate of 63.4%. Tisa-cel and axi-cel dominated the literature with 51.7% (n = 601) and 554 (47.6%) publications respectively. Ide-cel appeared in 152 (13.1%) publications, liso-cel in 125 (10.7%), and cilta-cel in 120 (10.3%). Brexu-cel was the least represented with 106 (9.1%) publications. The retrieved publications received 57,097 citations (mean = 49.1 citations per article; H-index = 103). Hematology and oncology-related journals were most prolific. The United States led global research output with 694 (59.7%) publications. Research output from European countries showed strong dependence on U.S.-based partnerships. Institutionally, the University of Texas MD Anderson Cancer Center, with 132 publications, was the leading institutions, followed by Moffitt Cancer Centre, and Memorial Sloan-Kettering Cancer Center. Authorship analysis revealed significant collaborative efforts, averaging 10.9 authors per article. Co-authorship map revealed academia-industry partnership. Temporal analysis of keywords revealed an evolution from CD19 target research (tisa-cel and axi-cel) to BCMA focused therapies (ide-cel and celta-cel). Thematic analysis showed four research themes: (1) molecular, therapeutic, and regulatory development of CAR-T constructs; (2) outcome of clinical trials; (3) economic and policy dimension of CAR-T therapy; and (4) treatment of relapsed and refractory multiple myeloma. Conclusions This study offers a translationally relevant perspective for clinicians, researchers, and policymakers, and underscores the evolving priorities in therapeutic development, access, and sustainability in precision oncology.

27 April 2026 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
MSMoutaz Sweileh
Moutaz Sweileh
Disruption of cellular proteostasis leads to the accumulation and persistence of pathogenic proteins that drive oncogenesis. Key oncogenic and tumor suppressor proteins are frequently dysregulated in cancer, yet remain challenging to target by conventional small-molecule inhibitors. Targeted protein degradation (TPD), particularly through Proteolysis Targeting Chimeras (PROTACs) and molecular glues, has emerged as a transformative strategy that enables catalytic and selective elimination of disease-driving proteins. This study aimed to systematically map the global scientific landscape of TPD research in oncology using bibliometric methods. A comprehensive bibliometric analysis was conducted using the Scopus database covering articles published between January 2000 and December 2025. Bibliometric indicators including publication trends, compound annual growth rate (CAGR), citations, H-index, authorship pattern, and institutional contributions were analyzed. Network visualization of keyword co-occurrence, chronological evolution, and international collaboration were performed using VOSviewer. A total of 1334 publications were identified, demonstrating exponential growth, particularly after 2018, with a CAGR of 51.9% (2016–2025). The field is highly interdisciplinary, dominated by biochemistry, pharmacology, and chemistry. The dataset exhibited a high H-index (111), reflecting rapid intellectual maturation. Authorship analysis revealed a median of 10 authors per article, underscoring extensive collaboration. China and the United States emerged as dominant contributors, forming central hubs in the global research network. PROTAC technology represented the primary research focus, with strong association to ubiquitin–proteasome mechanisms and oncogenic targets such as BRD4, MYC, androgen receptor, and estrogen receptor. Highly cited articles were predominantly methodological, highlighting foundational advances in degrader design and mechanism. TPD research is rapidly evolving toward clinically driven innovations with emerging focus on advanced delivery systems, lysosome-targeting strategies, next-generation degrader design strategies, and combination therapies to overcome pharmacokinetic and therapeutic limitations. TPD research in oncology is undergoing rapid expansion and transitioning from conceptual innovation to translational application. PROTACs dominate the field due to their modularity and catalytic efficiency, although challenges remain, including pharmacokinetic limitations, restricted E3 ligase diversity, and potential resistance mechanisms. Overall, TPD represents a paradigm shift toward event-driven pharmacology with significant potential to transform precision oncology by enabling the therapeutic elimination of previously intractable targets. The online version contains supplementary material available at 10.1007/s00432-026-06482-0.

28 September 2026 in Cureus
Verified
Journal Article
Open access
PDF file
MSMoutaz Sweileh
Moutaz Sweileh
HAHisham Asaad
Hisham Asaad
AAAya Abdi
Aya Abdi
MSMoutaz Sweileh
Moutaz Sweileh
Severe vitamin B12 deficiency can rarely present as pseudo-thrombotic microangiopathy (pseudo-TMA), characterized by anemia, thrombocytopenia, biochemical hemolysis, and schistocytosis, thereby mimicking thrombotic thrombocytopenic purpura (TTP). Concomitant abnormalities of conventional coagulation parameters may further complicate the presentation by raising concern for disseminated intravascular coagulation (DIC). We report an unusual presentation of severe combined vitamin B12 and folate deficiency with pseudo-TMA and a DIC-like coagulation profile. A 56-year-old man with severe combined vitamin B12 and folate deficiency presented with profound pancytopenia, schistocytosis, biochemical hemolysis, inadequate reticulocytosis, and megaloblastic hematopoiesis despite normal mean corpuscular volume (MCV). Elevated D-dimer, prolonged prothrombin time (PT), and reduced fibrinogen produced a DIC-like profile. Hematologic and coagulation parameters improved within one week of starting vitamin B12 replacement; folic acid was initiated after that first week. Recognition of megaloblastic pseudo-TMA and its potential coagulation abnormalities may prevent misdiagnosis and unnecessary TTP-directed therapy.

3 April 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
MSMoutaz Sweileh
Moutaz Sweileh
Background Spatial transcriptomics (ST) is a rapidly transforming cancer research by enabling spatially resolved gene expression profiling within intact tissues. However, the growth, structure, and thematic evolution of research on ST research in oncology have not been comprehensively mapped. Objective This study aims to map and analyze global research trends of ST in oncology, identifying key contributors, collaborations, thematic focus areas, and technological evolutions in the field. Method A bibliometric analysis was conducted using data extracted from Scopus database. VOSviewer tool was used to construct knowledge maps reflecting thematic clusters and intellectual clusters in ST-oncology research. Quantitative indicators were evaluated to identify historical evolution, key players, and research hotspots. Results The study identified 987 publications on ST in oncology. The annual growth of publications showed a significant surge over the past five years. China and the United States emerged as leading contributors with high levels of intra- and inter-national collaboration. Key journals included Nature Communications and Frontiers in Immunology. Academic and research institutions based in China dominated the field. Co-occurrence mapping identified the following high-frequency keywords: “tumor microenvironment”, “single-cell RNA sequencing”, and spatial resolution suggesting strong emphasis on integrating spatial biology with precision oncology. Bibliographic coupling illustrated a clustering around barcoding technologies and immune-oncology interfaces. The overlay visualization suggested a shift toward high resolution imaging, multi-omics integration, and AI-supported analytics. Conclusion ST-oncology research is expanding rapidly with clear shifts toward higher resolution and integrative analytical frameworks. These findings provide a structured overview of the field’s knowledge base and can inform researchers, funders, and stakeholders about leading about leading contributors and emerging directions.